Results 111 to 120 of about 79,407 (254)

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont   +5 more
wiley   +1 more source

Prevalence of Sleep Apnea and Sleepiness in Adults With and Without HIV in Mwanza, Tanzania: Baseline Results From an Ongoing Cohort Study

open access: yesJournal of Sleep Research, EarlyView.
ABSTRACT We conducted a cross‐sectional analysis of the baseline survey of participants aged > 30 years enrolled in the Mwanza HIV&CVD Cohort in Tanzania. Our primary objective was to examine the association between HIV status and sleep apnea (SA).
Godfrey A. Kisigo   +9 more
wiley   +1 more source

Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide.

open access: yesJournal of Antimicrobial Chemotherapy, 2019
OBJECTIVES Tenofovir alafenamide produces lower plasma tenofovir and higher intracellular tenofovir diphosphate (DP) concentrations than tenofovir disoproxil fumarate but it is likely a victim of interactions with rifampicin.
M. Cerrone   +9 more
semanticscholar   +1 more source

Tenofovir disoproxil fumarate induces peripheral neuropathy and alters inflammation and mitochondrial biogenesis in the brains of mice. [PDF]

open access: yes, 2019
Mounting evidence suggests that antiretroviral therapy (ART) drugs may contribute to the prevalence of HIV-associated neurological dysfunction. The HIV envelope glycoprotein (gp120) is neurotoxic and has been linked to alterations in mitochondrial ...
Achim, Cristian L   +11 more
core  

Highlights from the 24th conference on retroviruses and opportunistic infections, 13-16 February 2017, Seattle, Washington, USA [PDF]

open access: yes, 2017
From the 13th to 16th February 2017, researchers from around the world convened for the 24th annual Conference on Retroviruses and Opportunistic Infections (CROI) at the Washington State Convention Center in Seattle, Washington.
Bhagani, Sanjay   +12 more
core   +5 more sources

Meta‐Analysis: High anti‐HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment

open access: yesAlimentary Pharmacology &Therapeutics, Volume 63, Issue 5, Page 592-602, March 2026.
This meta‐analysis demonstrates a significantly lower risk for HBV reactivation on rituximab if anti‐HBs is > 100 iU/L (3.5%, CI: 1.8%–6.9%) vs. anti‐HBs between 10 and 100 iU/L (13.8%, CI: 8.8%–20.8%) and anti‐HBs negative (27.3%, CI: 20.0%–36.0%). Thus, if anti‐HBs titer is > 10 iU/L, monitoring could be considered.
Shiva Poola   +4 more
wiley   +1 more source

Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries

open access: yesJournal of Virus Eradication, 2015
Background: In 2013, an estimated 686,000 people died from hepatitis B virus (HBV) infection worldwide. Mass treatment programmes for hepatitis B will require very low drug costs.
Andrew Hill   +6 more
doaj   +1 more source

Switching to Tenofovir Therapy Versus Continuation of Entecavir for Patients With Hepatitis B Virus Infection: A Systematic Review and Meta‐Analysis

open access: yesJGH Open
Background Hepatitis B virus (HBV) infection causes liver disease, including hepatocellular carcinoma. Controlling viral activity is crucial to reducing complications.
Muhammad Shahzil   +10 more
doaj   +1 more source

Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]

open access: yes, 2018
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core   +1 more source

Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa? [PDF]

open access: yes, 2017
This version is the Accepted Manuscript and is published in final edited form as: AIDS. 2017 January 02; 31(1): 147–157. doi:10.1097/QAD.0000000000001307OBJECTIVE: We assessed the relationship between phasing out stavudine in first-line antiretroviral ...
Bor, Jacob   +15 more
core   +2 more sources

Home - About - Disclaimer - Privacy